Actavis to launch novel pain medication in the US

Actavis to launch novel pain medication in the US

21 Dec 2011

Actavis today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) to commercialize MoxDuo® IR in the United States.

Under the terms of the LOI, Actavis gets exclusive rights to launch and market MoxDuo® IR, a patented 3:2 ratio fixed dose combination of morphine and oxycodone for the USD2.5bn US acute pain market. The product launch in the US is expected in Q3 2012. Pre-launch preparations will begin immediately.

Claudio Albrecht, CEO Actavis:
"This partnership represents a major step in our strategy to further strengthen our position as one of the major players in the segment of pain management in the US. Furthermore, as this latest development highlights, Actavis is serious in its quest to be ahead of the changing generic pharmaceutical industry. In the future, there will not be such a clear difference between innovator and generic companies. The lines between the two models are blurring. The generics business as we know it today will be gone within the next ten years."

Strategic partnership with QRxPharma to commercialise MoxDuo® IR for the USD2.5 Billion US acute pain market
Actavis intends for MoxDuo® IR to be a flagship product in the Company's growing pain management franchise. This transaction builds on Actavis success with the currently marketed Kadian® Extended Release Morphine Sulfate capsules, and a broad array of generic scheduled narcotics offerings. Kadian® has been manufactured by the Company for 15 years and marketed by Actavis since 2008. The Company's analgesic sales force for its branded products will expand significantly and have MoxDuo® IR as a primary focus in the US pain market.

Actavis' CEO for the US, Doug Boothe:
"Actavis Inc. is a company with deep experience and solid results in pain management. Building on the success of Kadian®, we believe the QRxPharma partnership offers significant opportunity to leverage the talent of our team to establish MoxDuo® IR as a preferred option in the US acute pain marketplace. We believe MoxDuo® IR has tremendous sales potential."

As one of the world's largest manufacturers of branded and generic opioids, Actavis may serve as a contract supplier for MoxDuo® IR in the US market. Under the terms of the LOI, QRxPharma retains full flexibility to market MoxDuo® IR outside the US.

Dr. John Holaday, Managing Director and CEO, QRxPharma:
"After analysis of several other licensing proposals, it was clear Actavis was the strategic choice for the Company. Their experience in the manufacturing, distribution, marketing and sales of both patented and generic opioid products enabled a partnership structure with QRxPharma that will accelerate revenues and maximise shareholder value."

The agreement also provides Actavis with an option for US marketing and sales rights of QRxPharma's chronic pain controlled release Dual-Opioid, MoxDuo® CR, as well as its hospital based intravenous formulation, MoxDuo® IV. The exercise of the option for MoxDuo® CR by Actavis is contingent upon the achievement of certain sales milestones for MoxDuo® IR. The option for MoxDuo® IV will lapse on a date certain if not exercised by Actavis.

Enquiries
Gerard Farrell
Actavis US Press Line
Tel: (+1) 973 889 6689
E-mail: [email protected]

About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.

Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the U.S. and seeks strategic partnerships for worldwide markets.

QRxPharma's lead product candidate, immediate release MoxDuo®, now awaits approval by the US Food and Drug Administration (FDA). Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo®, as well as other pipeline technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.

 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.